Paradigm Biopharmaceuticals Ltd has released a press release.
Primary Endpoint Achieved in Phase 2 MPS VI Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Paradigm Receives $7.36m R&D Tax Incentive Refund
- Security Class Reinstatement to Quotation PARO
- Successful completion of Retail Entitlement Offer
- Security Class Suspension from Quotation PARO
- Paradigm to Recommence Trading
Later from Paradigm Biopharmaceuticals
- Half Yearly Report and Accounts
- Type D Response Submitted and Received by the US FDA
- Appendix 4E and 2024 Annual Report
- PAR receives positive response from US FDA for phase 3
- Paradigm Investor Update
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals